Yanjing Guo

411 total citations
16 papers, 321 citations indexed

About

Yanjing Guo is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yanjing Guo has authored 16 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Yanjing Guo's work include Bone Metabolism and Diseases (3 papers), Epigenetics and DNA Methylation (3 papers) and Hedgehog Signaling Pathway Studies (2 papers). Yanjing Guo is often cited by papers focused on Bone Metabolism and Diseases (3 papers), Epigenetics and DNA Methylation (3 papers) and Hedgehog Signaling Pathway Studies (2 papers). Yanjing Guo collaborates with scholars based in China, Sweden and United States. Yanjing Guo's co-authors include Wei‐Qiang Gao, Helen He Zhu, Chaping Cheng, Zhongzhong Ji, Xue Wang, Mingliang Chu, Huifang Zhao, Dawei Xu, Yuxiang Fang and Li Li and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Yanjing Guo

14 papers receiving 318 citations

Peers

Yanjing Guo
Chenfeng Wang China
Jinfeng Gan China
Yunping Zhao China
Davida Kamara United States
Song-Chang Lin United States
Sarah Koushyar United Kingdom
Shuhang Qin China
Benjamin T. Dake United States
Runyi Ye China
Olena Preobrazhenska Canada
Chenfeng Wang China
Yanjing Guo
Citations per year, relative to Yanjing Guo Yanjing Guo (= 1×) peers Chenfeng Wang

Countries citing papers authored by Yanjing Guo

Since Specialization
Citations

This map shows the geographic impact of Yanjing Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanjing Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanjing Guo more than expected).

Fields of papers citing papers by Yanjing Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanjing Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanjing Guo. The network helps show where Yanjing Guo may publish in the future.

Co-authorship network of co-authors of Yanjing Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Yanjing Guo. A scholar is included among the top collaborators of Yanjing Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanjing Guo. Yanjing Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ji, Dongmei, Yanjing Guo, Xin Liu, et al.. (2024). A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing.. Journal of Clinical Oncology. 42(16_suppl). e18062–e18062. 2 indexed citations
2.
3.
4.
5.
Yang, Ruijia, Yanjing Guo, Zhou Ma, et al.. (2023). Bardoxolone methyl ameliorates osteoarthritis by inhibiting osteoclastogenesis and protecting the extracellular matrix against degradation. Heliyon. 9(2). e13080–e13080. 12 indexed citations
6.
Yang, Ruijia, et al.. (2023). FTY720 Attenuates LPS-Induced Inflammatory Bone Loss by Inhibiting Osteoclastogenesis via the NF-κB and HDAC4/ATF Pathways. Journal of Immunology Research. 2023. 1–14. 6 indexed citations
7.
Liu, Xin, Chengcheng Gong, Jieyun Zhang, et al.. (2023). Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study. Cancer Research and Treatment. 55(3). 1001–1010. 10 indexed citations
8.
Guo, Yanjing, Xinyu Chen, Xiaowei Zhang, & Xichun Hu. (2023). UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb. Frontiers in Oncology. 13. 992233–992233. 11 indexed citations
9.
Xu, Wenbin, Yining Wang, Yanjing Guo, et al.. (2021). Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways. Frontiers in Endocrinology. 12. 736863–736863. 16 indexed citations
10.
Wang, Minglei, Wenqin Luo, Yu Zhang, et al.. (2019). Trim32 suppresses cerebellar development and tumorigenesis by degrading Gli1/sonic hedgehog signaling. Cell Death and Differentiation. 27(4). 1286–1299. 14 indexed citations
11.
Cheng, Chaping, Zhongzhong Ji, Yaru Sheng, et al.. (2018). Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling. Theranostics. 8(17). 4633–4648. 33 indexed citations
12.
Zhang, Kai, Yanjing Guo, Xue Wang, et al.. (2017). WNT/β-Catenin Directs Self-Renewal Symmetric Cell Division of hTERThigh Prostate Cancer Stem Cells. Cancer Research. 77(9). 2534–2547. 112 indexed citations
13.
Guo, Yanjing, Kai Zhang, Chaping Cheng, et al.. (2017). Numb−/low Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling. Clinical Cancer Research. 23(21). 6744–6756. 37 indexed citations
14.
Chu, Mingliang, et al.. (2015). Regulation and Methylation of Tumor Suppressor MiR-124 by Androgen Receptor in Prostate Cancer Cells. PLoS ONE. 10(4). e0116197–e0116197. 27 indexed citations
15.
Guo, Yanjing, et al.. (2013). Cytokeratin 18 Is Not Required for Morphogenesis of Developing Prostates but Contributes to Adult Prostate Regeneration. BioMed Research International. 2013. 1–8. 5 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chenfeng Wang Breakdown of academic impact, for papers by Jinfeng Gan Breakdown of academic impact, for papers by Yunping Zhao Breakdown of academic impact, for papers by Davida Kamara Breakdown of academic impact, for papers by Song-Chang Lin Breakdown of academic impact, for papers by Sarah Koushyar Breakdown of academic impact, for papers by Shuhang Qin Breakdown of academic impact, for papers by Benjamin T. Dake Breakdown of academic impact, for papers by Runyi Ye Breakdown of academic impact, for papers by Olena Preobrazhenska
Rankless by CCL
2026